Inhibrx Balance Sheet Health
Financial Health criteria checks 5/6
Inhibrx has a total shareholder equity of $11.6M and total debt of $208.2M, which brings its debt-to-equity ratio to 1799.9%. Its total assets and total liabilities are $288.6M and $277.0M respectively.
Key information
1,799.9%
Debt to equity ratio
US$208.21m
Debt
Interest coverage ratio | n/a |
Cash | US$252.48m |
Equity | US$11.57m |
Total liabilities | US$277.01m |
Total assets | US$288.58m |
Recent financial health updates
Recent updates
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Jun 07Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?
May 13Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23Financial Position Analysis
Short Term Liabilities: INBX's short term assets ($274.5M) exceed its short term liabilities ($71.9M).
Long Term Liabilities: INBX's short term assets ($274.5M) exceed its long term liabilities ($205.1M).
Debt to Equity History and Analysis
Debt Level: INBX has more cash than its total debt.
Reducing Debt: INBX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INBX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INBX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.9% each year